ESM1 Drives Bladder Cancer Immune Evasion via the SPP1 Signaling Pathway
Multi-omics analysis reveals ESM1 as a key immunoevasion mediator in bladder cancer, suppressing immune cell infiltration and enabling tumor escape.
Summary
A large-scale multi-omics study identified Endothelial cell-specific molecule 1 (ESM1) as significantly overexpressed in bladder cancer tissues at both mRNA and protein levels across 1,558 clinical samples. ESM1 was found to be enriched specifically in lymphatic endothelial cells and activates the SPP1 signaling pathway to promote immune evasion and metastasis. High ESM1 expression suppressed T-cell receptor and Fc gamma R-mediated immune pathways, reduced immune cell infiltration, and increased tumor purity in the tumor microenvironment. Additionally, miR-129-5p was identified as an upstream regulator of ESM1, showing downregulation in bladder cancer and strong early diagnostic performance. ESM1 achieved an AUC of 0.94 for distinguishing cancerous from normal tissue, highlighting its potential as a clinically actionable biomarker.
Detailed Summary
Bladder cancer remains a challenging malignancy with high recurrence rates and limited effective therapies. Understanding the tumor microenvironment (TME) is increasingly recognized as essential for developing better diagnostic and therapeutic tools. This study focused on ESM1, a soluble dermatan sulfate proteoglycan previously implicated in cancer progression, to determine its role specifically in bladder cancer biology and immune regulation.
The researchers integrated data from 1,558 clinical samples spanning 19 mRNA datasets (pooled into 13 cohorts) and 7 miRNA datasets drawn from GEO, TCGA, and ArrayExpress. They validated ESM1 protein expression via immunohistochemistry on 195 in-house tissue samples (149 bladder cancer, 46 controls). Epigenetic regulation was explored using Cistrome Data Browser with ChIP-Seq, ATAC-seq, and histone modification data. Single-cell RNA sequencing (scRNA-seq) from GSE277524 was analyzed using Seurat, SingleR, CellChat, and CytoTRACE packages. Immune pathway enrichment was assessed via GSEA and ssGSEA, with immune infiltration quantified by ESTIMATE and TIMER algorithms.
ESM1 mRNA and protein were significantly overexpressed in bladder cancer compared to normal tissues (p<0.05), with diagnostic AUC of 0.94. Epigenetic analysis identified three major transcription factors regulating ESM1 transcription, along with active enhancer and promoter regions and silencer elements. At the single-cell level, ESM1 was predominantly enriched in lymphatic endothelial cells and was shown to participate in the SPP1 signaling pathway—a known driver of immune evasion and tumor metastasis. High ESM1 expression correlated with suppression of T-cell receptor signaling and Fc gamma R-mediated immune pathways, reduced stromal and immune scores, lower immune cell infiltration (B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, dendritic cells), and increased tumor purity. ESM1 expression also significantly associated with patient age, ethnicity, and clinical stage.
Upstream miRNA analysis identified miR-129-5p as a direct regulator of ESM1, with miR-129-5p downregulated in both bladder cancer tissues and blood samples. This miRNA demonstrated excellent early cancer screening ability, suggesting a regulatory axis where miR-129-5p loss leads to ESM1 upregulation and subsequent immune suppression in the TME.
These findings position ESM1 as a multifaceted oncogenic mediator in bladder cancer—driving immunoevasion through the SPP1 pathway, reshaping the TME, and correlating with clinically relevant patient characteristics. However, the study is primarily bioinformatic and IHC-based; functional validation through in vitro or in vivo experiments is needed to confirm causality. The clinical utility of miR-129-5p as a blood-based biomarker also warrants prospective validation.
Key Findings
- ESM1 mRNA and protein are significantly overexpressed in bladder cancer, achieving a diagnostic AUC of 0.94.
- ESM1 is enriched in lymphatic endothelial cells and activates the SPP1 pathway to promote immune evasion and metastasis.
- High ESM1 expression suppresses T-cell receptor and Fc gamma R immune pathways, reducing immune cell infiltration in the TME.
- miR-129-5p is downregulated in bladder cancer and directly regulates ESM1, offering potential as a blood-based early screening biomarker.
- ESM1 expression correlates significantly with patient age, ethnicity, and clinical disease stage.
Methodology
The study used multi-omics integration across 1,558 clinical samples including mRNA/miRNA datasets from GEO, TCGA, and ArrayExpress, complemented by in-house IHC validation on 195 tissue samples. Single-cell RNA-seq analysis (GSE277524) employed Seurat, CellChat, and CytoTRACE; epigenetic regulation was explored via Cistrome Data Browser with ChIP-Seq and ATAC-seq data. Immune infiltration was quantified using ssGSEA, ESTIMATE, and TIMER algorithms.
Study Limitations
The study is predominantly computational and IHC-based, lacking functional in vitro or in vivo experiments to establish causal mechanisms. The single-cell sequencing dataset was limited to one cohort (GSE277524), and prospective clinical validation of miR-129-5p as a blood biomarker has not yet been performed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
